Vigamox (Moxifloxacin Alcon) Augndropar, lausn 5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vigamox (moxifloxacin alcon) augndropar, lausn 5 mg/ml

novartis healthcare a/s - moxifloxacinum hýdróklóríð - augndropar, lausn - 5 mg/ml

Flúoxetín Actavis Lausnartafla 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

flúoxetín actavis lausnartafla 20 mg

actavis group ptc ehf. - fluoxetine hydrochloride - lausnartafla - 20 mg

Fluoxetin WH Hart hylki 20 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

fluoxetin wh hart hylki 20 mg

williams & halls ehf - fluoxetine hydrochloride - hart hylki - 20 mg

Scemblix Evrópusambandið - íslenska - EMA (European Medicines Agency)

scemblix

novartis europharm limited - asciminib hydrochloride - kyrningahvítblæði, mergbreytilegt, langvinnt, bcr-abl jákvætt - Æxlishemjandi lyf - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Donepezil Actavis Filmuhúðuð tafla 10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

donepezil actavis filmuhúðuð tafla 10 mg

actavis group ptc ehf. - donepezil hydrochloride - filmuhúðuð tafla - 10 mg

Donepezil Actavis Filmuhúðuð tafla 5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

donepezil actavis filmuhúðuð tafla 5 mg

actavis group ptc ehf. - donepezil hydrochloride - filmuhúðuð tafla - 5 mg

Vanflyta Evrópusambandið - íslenska - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - kyrningahvítblæði, mergbólga - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Aloxi Evrópusambandið - íslenska - EMA (European Medicines Agency)

aloxi

helsinn birex pharmaceuticals ltd. - palonósetrón hýdróklóríð - vomiting; cancer - uppsölulyf og antinauseants, , serótónín (5ht3) - mótlyf - aloxi er fram í fyrir fullorðna:fyrirbyggja bráð ógleði og uppköstum tengslum með mjög emetogenic krabbamein lyfjameðferð,koma í veg fyrir ógleði og uppköstum tengslum við nokkuð emetogenic krabbamein lyfjameðferð. aloxi er ætlað í börn sjúklingar 1 mánuði aldri og eldri fyrir:fyrirbyggja bráð ógleði og uppköstum tengslum með mjög emetogenic krabbamein lyfjameðferð og koma í veg fyrir ógleði og uppköstum tengslum við nokkuð emetogenic krabbamein lyfjameðferð.

Trilafon Dekanoat (Trilafon dekanoat) Stungulyf, lausn 108 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

trilafon dekanoat (trilafon dekanoat) stungulyf, lausn 108 mg/ml

orion corporation - perphenazinum dekanóat - stungulyf, lausn - 108 mg/ml

Firmagon Evrópusambandið - íslenska - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - degarelix - blöðruhálskirtli - innkirtla meðferð - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.